{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:59:39Z","timestamp":1787169579161,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20150237"],"award-info":[{"award-number":["20150237"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20190229"],"award-info":[{"award-number":["20190229"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20220859"],"award-info":[{"award-number":["20220859"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20210407"],"award-info":[{"award-number":["20210407"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20190226"],"award-info":[{"award-number":["20190226"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["987589"],"award-info":[{"award-number":["987589"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016-02043"],"award-info":[{"award-number":["2016-02043"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2018-1256"],"award-info":[{"award-number":["2018-1256"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ijantimicag.2024.107302","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T19:57:43Z","timestamp":1723579063000},"page":"107302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosis"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3398-2421","authenticated-orcid":false,"given":"Johanna","family":"Kuhlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Davies Forsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Skagerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerker","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2696-437X","authenticated-orcid":false,"given":"Ramona","family":"Groenheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Mansj\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Werngren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bruchfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107302_bib0001","first-page":"603","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"Zhang","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0002","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0003","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis","volume":"26","author":"Jaspard","year":"2020","journal-title":"France. Emerg Infect Dis."},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0004","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0005","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/ciad653","article-title":"The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis","volume":"78","author":"Hasan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0006","series-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","year":"2019"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0007","series-title":"WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update","year":"2022"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0008","first-page":"640","article-title":"Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis","volume":"9","author":"Laserson","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0009","series-title":"Definitions and reporting framework for tuberculosis\u20132013 revision","year":"2013"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0010","article-title":"Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis","volume":"60","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0011","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ijantimicag.2017.01.017","article-title":"Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis","volume":"49","author":"Kamp","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0012","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/AAC.40.4.839","article-title":"In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents","volume":"40","author":"Zurenko","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0013","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00002018-199410020-00001","article-title":"Harmonisation in pharmacovigilance","volume":"10","author":"Edwards","year":"1994","journal-title":"Drug Saf"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0014","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0015","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/jac\/dkac019","article-title":"Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study","volume":"77","author":"Wasserman","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0016","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac485","article-title":"Association between increased linezolid plasma concentrations and the development of severe toxicity in multidrug-resistant tuberculosis treatment","volume":"76","author":"Eimer","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0017","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1183\/09031936.00035114","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China","volume":"45","author":"Tang","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0018","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fphar.2017.00086","article-title":"Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review","volume":"8","author":"Kerckhove","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107302_bib0019","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","article-title":"Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics","volume":"42","author":"Rao","year":"2020","journal-title":"Ther Drug Monit"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924002188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:28:23Z","timestamp":1778549303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924002188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0924857924002188"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107302","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107302"}}